Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...

Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...

PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, People’s Republic of China ...

1Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China. 2Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Benxi, China. Search for other works ...

A thyroglobulin antibody (TgAb) test looks for certain antibodies that attack the thyroid. The presence of TbAb in high levels may indicate that someone has an autoimmune condition. To conduct a ...